Median Technologies SA

Median Technologies is a French medical technology company that specializes in innovative software as a medical device (SaMD) and imaging services, leveraging artificial intelligence (AI) to enhance the accuracy of early cancer diagnoses and treatments. The company focuses on both oncology clinical trials and direct cancer patient care. Headquartered in Valbonne, France, Median Technologies also maintains subsidiaries in the United States and China.

Median Technologies offers two primary platforms: iCRO and eyonis®. The iCRO platform provides best-in-class medical image analysis and management services for oncology clinical trials, supporting biopharmaceutical companies and Contract Research Organizations (CROs) in accelerating drug development. The eyonis® platform is an AI/ML-based suite of SaMD designed for early cancer diagnosis and monitoring. Notably, eyonis® LCS, a specific product within this suite, is developed for lung cancer screening, while other applications target conditions like liver cancer.

In recent developments, Median Technologies received FDA 510(k) clearance for its eyonis® LCS lung cancer screening tool in February 2026, paving the way for its commercialization in the United States. To spearhead this launch, Oran Muduroglu was appointed President of Median eyonis Inc., the company's U.S. subsidiary. The company has also entered into a non-exclusive distribution agreement with Tempus AI, Inc. to integrate eyonis® LCS into clinical workflows via the Tempus Pixel platform. Fredrik Brag serves as the CEO and Founder of Median Technologies. The company has extended its cash runway until at least Q4 2026 following successful financing efforts, and its iCRO order backlog reached a record €79.8 million as of March 31, 2026.